Global Microbiome Sequencing Services market is expected to witness a CAGR of 19.21% during the forecast period. Certain factors that are driving the market growth include huge investment in microbiome research, rise in demand for NGS services, the decline in the cost of NGS sequencing, the surge in genomic research and widening application area of microbiome sequencing.
NGS technologies exhibit a paradigm shift in sequencing capabilities. This expertise has been extensively applied to biological research, resulting in significant and remarkable insights into the molecular biology of cells. Over the past 10 years, budgets allocated to R&D have increased steadily. Pharmaceutical companies want their drugs to perform well. However, huge cost is involved in developing such drugs, and immense funding is required to market these drugs.
Click the link to get a free Sample Copy of the Report at:
The most critical steps in the drug discovery process in pharmaceutical companies is target identification and single nucleotide polymorphisms (SNPs), which are broadly used to analyze its individual characteristics for target identification. NGS is improving the resolution of bacterial species identification, with the use of various identification methods. Thus, the rising demand for NGS services in various biological sectors is spurring the growth of the market. Additionally, many companies are concentrating on novel exome sequencing and RNA sequencing applications in niche market segments.
However, despite increased access and reduced cost of sequencing, data analysis and interpretation still present a challenge to researchers using NGS technology. Thousands of whole genomes and hundreds and thousands of exomes have been sequenced already. Microbiome sequencing is generating a huge chunk of data, which needs to be understood using advanced software. Thus, the lack of technicians in the interpretation of sequencing data is one of the major restricting factors for the growth of the microbiome sequencing services market.
Scope of the Report
Microbiome is the unique collection of trillions of microorganisms, in and on an individual’s body. The goal of human microbiome studies is to understand the role of microbes in health and disease. Human microbiome analysis is the study of microbial communities found in and on the human body. Microbiome sequencing is used to study microflora of human biota, with the goal of understanding human microbes and the role played by them in health and disease.
Inquire For Discount at:
Key Market Trends
Gastrointestinal disorders are Expected to Hold Significant Market Share in the Application Segment
Gastrointestinal disorders are inclusive of disorders, such as gastritis, peptic ulcer, inflammatory bowel disease, and pancreatitis. In addition, a group of conditions caused in the digestive tract may cause inflammatory bowel disease (IBD). Crohn’s disease and ulcerative colitis are the most common subtypes of IBD. iHMP (Human Microbiome Project) researchers are drawing conclusions, by collecting a public database consisting of time-bound information from several IBD patients studies. Along with a variety of relevant patient data, the database may also contain information about both, the composition of the gut microbiome over time in these patients, as well as the small molecules and proteins being produced by these microbes.
North America Dominates the Market and Expected to do Same in the Forecasted Period
The region, especially the United States, has the most active ecosystems for genomic research, which is supported by both government and industry players. The US government supports genomics research through various government bodies, like NHGRI (National Human Genome Research Institute, the United States), which have supported the work on sequencing of the human genome, and fund research on the genome’s structure, function, and role in health and disease. Presence of a conducive research environment for genomic exploration, which is supported by adequate government funding and industry support, ensures the growth of the market for microbiome sequencing services in North America, over the forecast period.
The Global Microbiome Sequencing Services market is highly competitive and consists of a number of major players. Companies like Baseclear BV, Clinical Microbiomics AS, Merieux Nutrisciences Corporations, EPIBIOME, Microbiome Insights Inc., Microbiome Therapeutics LLC, MR DNA, Second Genome, Ubiome Inc., Zymo Research Corp., among others, holds the substantial market share in the Microbiome Sequencing Services market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
Top Companies in the Global Market:
– Baseclear BV
– Clinical Microbiomics AS
– Merieux Nutrisciences Corporations
– Microbiome Insights Inc.
– Microbiome Therapeutics LLC
– MR DNA
– Second Genome
– Ubiome Inc.
– Zymo Research Corp.
Table of Contents:
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Huge Investment in Microbiome Research
4.2.2 Rise in Demand for NGS Services
4.2.3 Decline in the Cost of NGS Sequencing
4.2.4 Surge in Genomic Research and Widening Application Area of Microbiome Sequencing
4.3 Market Restraints
4.3.1 Ethical and Legal Issues Related to Genome Sequencing
4.3.2 Lack of Skilled Technicians for NGS Data Analysis
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1.1 Sequencing by Ligation (SBL)
5.1.2 Sequencing by Synthesis (SBS)
5.1.3 Shotgun Sequencing
5.1.4 Targeted Gene Sequencing
5.1.5 RNA Sequencing
5.1.6 Other Technologies
5.2.1 Gastrointestinal Diseases
5.2.2 Infectious Diseases
5.2.3 CNS Diseases
5.2.5 Other Applications
5.3 End User
5.3.1 Research and Academic Institutes
5.3.2 Pharmaceutical and Biotechnology Companies
5.3.3 Other End Users
5.4.1 North America
184.108.40.206 Rest of Europe
5.4.3 Asia Pacific
220.127.116.11 South korea
18.104.22.168 Rest of Asia-Pacific
5.4.4 Middle East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle East and Africa
5.4.5 South America
188.8.131.52 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Baseclear BV
6.1.2 Clinical Microbiomics AS
6.1.3 Merieux Nutrisciences Corporations
6.1.5 Microbiome Insights Inc.
6.1.6 Microbiome Therapeutics LLC
6.1.7 MR DNA
6.1.8 Second Genome
6.1.9 Ubiome Inc.
6.1.10 Zymo Research Corp.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS